Wa'el Hashad Wa'el Hashad, CEO, Longeveron – FDA designation enables expedited clinical development and regulatory review timelines for Lomecel-B™ – –...
Pepinemab is believed to block astrocyte reactivity, a key pathology driving Alzheimer’s progressionROCHESTER, N.Y., July 17, 2024 (GLOBE NEWSWIRE) --...
– 43% of Participants Showed Improvement on the UMSARS Activities of Daily Living Scale – – 29% of Participants had...
Following a thorough review of all strategic alternatives, ASLAN Pharmaceuticals Pte Ltd, the sole operating subsidiary of ASLAN Pharmaceuticals, has...
– 43% of Participants Showed Improvement on the UMSARS Activities of Daily Living Scale – – 29% of Participants had...
Dr. Arshad Khanani to chair the newly formed Medical Advisory BoardMELBOURNE, Australia and PRINCETON, N.J., July 17, 2024 (GLOBE NEWSWIRE)...
DURHAM, N.C., July 17, 2024 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO),...
Another Patent Granted for CytoMed's Allogeneic Induced Pluripotent Stem Cell (“iPSC”)-derived Hybrid Gamma Delta Natural Killer T (γδ NKT) cells...
Supports Development of Ancilia’s Unique Platform that Harnesses CRISPR’s Natural Function to Increase the Utility of Live Bacterial Products for Therapeutic...
RAMAT GAN, Israel, July 17, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing...
Company Announcement Net sales of DARZALEX® in the second quarter of 2024 totaled USD 2,878 millionGenmab receives royalties on worldwide...
Robust reduction in anti-VEGF injection treatment burden through Week 24 achieved in 30 patients at planned Phase 3 dose (3E10...
BASEL, Switzerland – 17th July 2024 - Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vector-based cancer...
- 6E10 combined with local prophylaxis selected for Phase 3 pivotal trials, with a favorable safety profile and potential best-in-class...
After four weeks of treatment, CT-996 demonstrated clinically meaningful weight loss of -7.3% (weight loss in placebo -1.2%; p <...
In a release issued under the same headline on July 12, 2024 by Onco360 Oncology Pharmacy, please note the change...
ORIC-944, a potential best-in-class PRC2 inhibitor, is being evaluated in combination with darolutamide and in combination with apalutamide in patients...
FOSTER CITY, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical...
VANCOUVER, BC / ACCESSWIRE / July 17, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to...
CHENGDU, China, July 16, 2024 /PRNewswire/ -- "Evolving DNA-Encoded Library Technology and Its Application for Innovative Drug Discovery" webinar will be...